PT - JOURNAL ARTICLE AU - Lisa R. Gerak AU - Charles P. France TI - Attenuation of the positive-reinforcing effects of ultra-potent fentanyl analogs, along with those of fentanyl and heroin, during daily treatment with methocinnamox (MCAM) in rhesus monkeys AID - 10.1124/jpet.122.001267 DP - 2022 Jan 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - JPET-AR-2022-001267 4099 - http://jpet.aspetjournals.org/content/early/2022/12/20/jpet.122.001267.short 4100 - http://jpet.aspetjournals.org/content/early/2022/12/20/jpet.122.001267.full AB - Without substantial intervention, the opioid crisis is projected to continue, underscoring the need to develop new treatments for opioid use disorder (OUD). One drug under development is the µ opioid receptor antagonist methocinnamox (MCAM), which appears to offer advantages over currently available medications; however, some questions remain about its potential utility, including its ability to block the effects of ultra-potent fentanyl analogs. The goal of this study was to examine its effectiveness in attenuating the abuse-related effects of the fentanyl analogs carfentanil and 3-methylfentanyl in monkeys responding for food or i.v. infusions under a choice procedure. These drugs were compared to fentanyl, heroin, methamphetamine, and cocaine. Food was preferred over saline, and there was a dose dependent increase in responding for drug over food with no marked decrease in response rates or number of choice trials completed for any of the 6 drugs studied. Naltrexone (0.032 mg/kg) antagonized choice of µ opioid receptor agonists, producing rightward shifts in dose-effect curves ranging from 27-fold (carfentanil) to 71-fold (heroin). In contrast, naltrexone was less effective in attenuating choice of methamphetamine or cocaine with curves obtained in the presence of naltrexone shifted <3-fold. Daily treatment with 0.032 mg/kg MCAM also antagonized the effects of opioids, shifting curves 20-fold (fentanyl) to 72-fold (heroin) rightward; MCAM did not significantly change dose-effect curves for methamphetamine or cocaine. Thus, antagonism by MCAM is similar across a variety of µ opioid receptor agonists, including ultra-potent fentanyl analogs, further supporting its potential utility as a treatment for OUD. Significance Statement Treatments for opioid use disorder (OUD) should attenuate the effects of a variety of opioids, including emerging threats like the ultra-potent fentanyl analogs. The novel μ opioid receptor antagonist MCAM is being developed to treat OUD because it provides long-lasting blockade of the reinforcing effects of heroin and fentanyl. The current study shows that MCAM attenuates the abuse-related effects of fentanyl analogs carfentanil and 3-methylfentanil, further supporting the utility of MCAM as a treatment for OUD.